Asymptomatic, metastatic hormone-refractory Prostate cancer

DrugDrug NameDrug Description
DB06688Sipuleucel-TAn autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
DrugDrug NamePhaseStatusCount